China starts building world-first supercomputer in orbit, launches key satellites
China is preparing to build the world's first supercomputer in orbit, according to reports. Therefore, Beijing has launched new satellites that are equipped with intelligent computing systems and inter-satellite communication links.The Asian giant sent 12 such satellites, part of the space-based Three-Body Computing Constellation, to orbit on May 14. To execute the mission, Chinese scientists used a Long March 2D rocket from the Jiuquan Satellite Launch Centre.Reports have revealed that the constellation could comprise thousands of satellites with a combined computing power of 1,000 peta operations per second (POPS).
Members of the Chinese Academy of Engineering have underlined that the constellation is expected to perform real-time data processing in orbit. Zhejiang Lab is jointly executing the project, a research institute based in Hangzhou, in collaboration with international partners.Wang Jian, a member of the Chinese Academy of Engineering and the director of the lab, revealed that the constellation could also address efficiency issues in traditional satellite systems and accelerate the integration of AI into space-based applications.
Wang had previously highlighted that the aim is to scale up the computing power of a single satellite from the teraflop to the petaflop level, and to achieve seamless interconnectivity between satellites, just like how the internet links individual computers.The member highlighted that with a computing constellation, even a single satellite can generate value. This has profound implications for the future of the space industry, according to Wang.
The launch, announced by China Aerospace Science and Technology Corporation (CASC), could greatly expand the boundaries of space applications. The construction of the constellation is expected to have far-reaching significance for the space industry.
Reports revealed that the initial satellites, which provide a combined computing power of 5 POPS and 30 terabytes of storage capacity, have the capability of in-orbit computing in space.
One satellite also carried an X-ray polarization detector developed by Guangxi University and the National Astronomical Observatories of the Chinese Academy of Sciences, which will be used to study gamma-ray bursts. Zhejiang Lab said it plans to collaborate with partners to deploy a constellation of more than 50 computing satellites this year.
The step is expected to mark the beginning of space-based cloud computing as a new capability.
It could open a new arena for strategic competition with the U.S. The ability to reduce bottlenecks for data from space and other capabilities could have potential economic, scientific, and military implications. While the U.S. and Europe have tested edge computing in space, China's collaborative effort appears to be the first to deploy a purpose-built AI constellation at scale, reported Space News.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Army surveillance balloons spotted over Tucson raise privacy concerns from advocates
An Aerostar high-altitude balloon as seen from the ground in Tucson. Photo by Dugan Meyer The U.S. Army and a private company are flying high-altitude surveillance balloons over the Tucson area, raising concerns among privacy advocates. Multiple high-altitude balloons have been spotted over the Tucson and Sierra Vista area for more than a week, with one balloon in particular staying over the area longer than any of the others. That balloon, with the registration number N257TH, has made headlines in the past. The balloon is owned by South Dakota aerospace company Aerostar, and in 2023 was mistaken for a Chinese spy balloon. The balloon is actually part of Aerostar's 'Thunderhead' balloon system, which has been doing multiple tests with the military and other contractors across the nation and around the globe. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX 'It is a technology that should not and constitutionally cannot be applied to the American people,' Jay Stanley, a senior policy analyst at the American Civil Liberties Union, told the Arizona Mirror. 'Even testing for eventual overseas use in legitimate combat theaters raises a lot of questions about what kind of data is being collected.' Aerostar would not answer specific questions about what type of testing was being done. The company referred additional questions to the U.S. Department of Defense and the Army, neither of which responded to multiple requests for comment. Aerostar confirmed that the flights were not connected to U.S. Customs and Border Patrol or Department of Homeland Security programs, 'however high-altitude balloons would be ideal for that type of mission,' Aerostar Culture and Communications Director Anastasia Quanbeck said in an email to the Mirror. 'By leveraging directional wind patterns at high altitudes, Aerostar's Thunderhead Balloon Systems offer groundbreaking capabilities for navigation and persistence over areas of interest,' she said. 'Aerostar Thunderhead Balloon Systems are capable of supporting intelligence, surveillance, and reconnaissance missions, as well as extending communications across wide distances, environmental monitoring, earth observation, and scientific research.' Quanbeck said she was not able to discuss the work the company does with the DOD or the Army. The 'Thunderhead' balloons are similar to 'spy balloons' that have made international headlines in recent years. They fly between 60,000 to 100,000 feet, twice the height of a commercial airliner, and can carry much larger payloads than a conventional drone or other small high altitude spy-planes. After Chinese spy-balloons made incursions into United States airspace in 2023, it was reported that the Army would begin pursuing a similar program to launch in 2025. Aerostar had previously been used in testing exercises. In the past, Aerostar has used blimps as surveillance systems. They were originally used for surveillance in combat zones overseas, then in 2012 were used along the border and still are often spotted at the border today. However, the systems that have been seen floating over southern Arizona in recent weeks have key differences from the blimps: they sit higher in the sky, are much larger, can stay afloat for much longer and can carry larger payloads. As reported by The War Zone, the Army has been researching using high-altitude balloons to deploy drone swarms into enemy territory far above the reach of enemy defenses. But the balloons over southern Arizona raise questions about privacy. In 2021, the 4th U.S. Circuit Court of Appeals ruled that the Baltimore Police Department's use of an aerial surveillance program that recorded virtually all of the city for 12 hours a day for six months was unconstitutional. Stanley thinks that case is pertinent when talking about what may be going on in Arizona. 'I think, if anything, it becomes more sensitive when the military is doing it,' Stanley said. Wide-area persistent surveillance or wide-area airborne surveillance is a technique that got its start in early days of the Iraq war but later would find itself in the hands of police. The technology has evolved from being very heavy but is now light enough to fit onto blimps and balloons. Aerostar and the military have not elaborated on what systems are aboard the balloons over the Tucson area, but Stanley said that systems like the ones Aerostar is developing could be used to deploy persistent surveillance systems, ultimately surveilling entire communities for days on end. The Thunderhead system boasts the ability to stay afloat for up to 30 days, and Aerostar has tested it along with its Zephyr platform, a new type of unmanned aircraft that also flies at high altitudes and has been tested in Arizona. That aircraft can stay in the air for up to two months. The balloon also could be carrying a variety of equipment, such as radar, lidar, GPS or cameras, Stanley said. While much of this equipment could be installed on a traditional aircraft, the balloon can stay afloat over an area at a higher altitude for longer durations, allowing for more persistent surveillance of an area, something that Stanley said can be a problem for everyday Americans. 'Following someone around for long periods of time reveals things about their life,' Stanley said. 'How often they go to the bar, associations, who they are hanging out with — and that is too much power for the government or anyone else to have over individuals.' SUPPORT: YOU MAKE OUR WORK POSSIBLE
Boston Globe
an hour ago
- Boston Globe
From no hope to a potential cure for a deadly blood cancer
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients -- a result never before seen in this disease. Advertisement These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr. Carl June, of the University of Pennsylvania. Bones collapse. June has seen patients who lost 6 inches in height. Advertisement 'It's a horrible, horrible death,' June said. 'Right now advanced myeloma is a death sentence.' (June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr. Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalized for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying skeptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Advertisement Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge -- helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study -- they had failed every treatment. They lived about a year. For Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Advertisement Taking the Legend CAR-T was difficult -- she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache -- or an old one -- can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' June said, costing more than $100,000 a year. The total cost over the years can be millions of dollars, June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is $555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr. Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Sharpless said. And for those like the patients in the new study who are living at least five years -- so far -- without disease, the outcome 'really is eye-popping,' Sharpless said. Advertisement 'That's getting to a point where you wonder if it will ever come back,' he added. This article originally appeared in
Yahoo
an hour ago
- Yahoo
High Growth Tech Stocks in Asia for June 2025
Amid a backdrop of easing inflation and renewed trade tensions, Asian markets are navigating a complex landscape that has seen smaller-cap indexes in the U.S. lag behind their larger counterparts, yet still manage to post positive returns. In this environment, identifying high-growth tech stocks in Asia requires careful consideration of companies that can leverage technological advancements and strategic positioning to thrive despite global economic uncertainties. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.68% 30.37% ★★★★★★ Fositek 26.71% 33.90% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Shanghai Huace Navigation Technology 24.40% 23.42% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ Shanghai BOCHU Electronic Technology 22.41% 23.53% ★★★★★★ Nanya New Material TechnologyLtd 22.72% 63.29% ★★★★★★ PharmaResearch 24.38% 25.85% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ JNTC 54.24% 87.93% ★★★★★★ Click here to see the full list of 495 stocks from our Asian High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Shenzhen Kinwong Electronic Co., Ltd. is involved in the research, development, production, and sale of printed circuit boards and electronic materials both in China and internationally, with a market cap of approximately CN¥29.28 billion. Operations: Kinwong Electronic focuses on the production and sale of printed circuit boards, generating a revenue of CN¥13.26 billion from this segment. Shenzhen Kinwong Electronic has demonstrated robust growth metrics, with revenue climbing to CNY 3.34 billion this quarter from CNY 2.74 billion in the previous year, marking a significant increase of 21.9%. This performance is bolstered by an earnings growth of 23.7% per year, outpacing the broader Chinese market's average. The company's commitment to innovation is evidenced by its substantial R&D investment, which aligns with industry trends towards advanced electronic solutions and might signal sustained future growth amidst a competitive tech landscape. Moreover, recent corporate activities including their annual general meeting and quarterly earnings announcements reflect active engagement and transparency with stakeholders, enhancing investor confidence in their operational strategies and market position. Delve into the full analysis health report here for a deeper understanding of Shenzhen Kinwong Electronic. Gain insights into Shenzhen Kinwong Electronic's past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Semitronix Corporation offers characterization and yield improvement solutions for the semiconductor industry both in China and internationally, with a market cap of CN¥11.49 billion. Operations: The company focuses on delivering solutions that enhance semiconductor characterization and yield, targeting both domestic and international markets. With a market capitalization of approximately CN¥11.49 billion, it operates within the semiconductor industry, providing specialized services aimed at optimizing production processes. Semitronix Corporation has shown a promising uptick in its financial health, with first-quarter sales jumping to CNY 66.48 million from CNY 43.9 million the previous year, reflecting a robust revenue growth rate of 51.7%. This performance is complemented by a significant reduction in net loss to CNY 13.71 million from CNY 22.9 million, indicating improving operational efficiency. The company's commitment to innovation and market adaptation is underscored by an R&D investment that aligns with evolving technological demands, positioning it well within the competitive landscape of Asia's high-growth tech sector. Get an in-depth perspective on Semitronix's performance by reading our health report here. Evaluate Semitronix's historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Taiwan Union Technology Corporation specializes in producing and distributing copper foil substrates, adhesive sheets, and multi-layer laminated boards both domestically and internationally, with a market capitalization of NT$51.79 billion. Operations: The company focuses on manufacturing and selling copper foil substrates, adhesive sheets, and multi-layer laminated boards to both domestic and international markets. It operates with a market capitalization of NT$51.79 billion. Taiwan Union Technology has demonstrated robust financial performance, with a 44.3% increase in Q1 sales year-over-year, reaching TWD 6.37 billion. This growth is supported by a significant rise in net income to TWD 671.95 million from TWD 451.84 million, reflecting an earnings growth of about 48.7%. The company's strategic focus on R&D is evident from its recent presentations at major tech conferences, positioning it well for sustained innovation and market competitiveness within Asia's tech sector. Click here to discover the nuances of Taiwan Union Technology with our detailed analytical health report. Examine Taiwan Union Technology's past performance report to understand how it has performed in the past. Discover the full array of 495 Asian High Growth Tech and AI Stocks right here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:603228 SZSE:301095 and TPEX:6274. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
